New Delhi, Dec 24 (PTI) The new strains of SARS-Cov-2 found in the United Kingdom and South Africa recently are less likely to change the efficacy of the vaccines under development, Vice President M Venkaiah Naidu was informed on Thursday by a senior scientist.
Besides, there is no evidence that suggests that the strains are associated with worse outcomes for patients, although they are more infective, he was told.
The same disease management strategies are expected to work for the variants too, an official statement said.
It said the director of the Centre for Cellular and Molecular Biology (CCMB), Dr Rakesh Mishra, on Thursday met Naidu in Hyderabad to brief him about the new strains of SARS-Cov-2 found in the UK and South Africa recently.
Mishra apprised the vice president that the mutations in the new strains are less likely to change the efficacy of the vaccines under development. Besides, there is no evidence that suggests the strains are associated with worse outcomes for the patients, although they are more infective, he said.
The same disease management strategies are expected to work for the variants too.
Naidu sought to know about the likely impact of the new strains in India and the work being carried out on various aspects of the novel coronavirus at the CCMB.
Dr K Lakshmi Rao, senior principal scientist at CCMB was also present.
Mishra informed the vice president that investigations were underway to find out whether the new strains are present in India.
Making a presentation to the vice president on the work being done at the CCMB on SARS-CoV-2, he said that the new strain was 71 per cent more infectious than the other strains.
A parallel strain identified in South Africa suggests that it affects younger people more, though more thorough research is required, he explained.
Mishra explained that the analysis of the genomes sequenced by the CCMB and other researchers in the country has revealed that the initial spread of the virus in India was mainly due to novel India specific clade, named I/A3i clade.
The I/A3i clade had likely entered India from other Southeast Asian countries. The analysis by the CCMB had further revealed that, with time, the weaker A3i clade was eventually replaced by the A2a clade, which is also the globally prevalent strain, the statement said.
He said the CCMB was the first non- Indian Council of Medical Research (ICMR) lab to start testing samples for the novel coronavirus SARS-CoV-2. It also established SoPs for other research institutes and universities for testing. It has trained more than 200 personnel from hospitals and other testing centres on the testing protocols.
CCMB itself has tested more than 50,000 samples so far by RT-PCR method. Together, all CSIR labs have tested more than 7,00,000 samples thus far, he said.
Mishra also said that the CCMB's dry swab Direct RT-PCR method has been approved by the ICMR. With partners like Apollo Hospitals, the kits will be manufactured in large numbers and they will reach masses through Spice Health's mobile testing labs, the statement said. PTI NAB ANB ANB